Pharma channel feed – Endpoints News

Pharma channel feed

FDA has about one month of user fee funds left, Gottlieb warns

7 years ago

TCR deal spree intensifies as Roche commits up to $2B in Adaptive Biotech to develop personalized cancer drugs

7 years ago

Shifting focus, Sanofi agrees to pay Regeneron $462M for an early wrap of their big I/O alliance

7 years ago

Remember that mega-blockbuster valuation AbbVie assigned to Rova-T? It’s starting to vanish — quietly

7 years ago

Joining forces with Skyhawk, C4 Therapeutics, Biogen buys more shots on goal on SMA, Alzheimer's

7 years ago

Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market

7 years ago

Sanofi sharpens focus on mRNA for cancer with equity investment in Germany's BioNTech

7 years ago

Jazz triggers Codiak’s first exosome alliance with a $76M ante and up to $1B-plus in milestones

7 years ago

After blueprinting R&D hub, AbbVie dishes out $105M for CD39 pact with Tizona's new CEO from Roche

7 years ago

Takeda builds arsenal for immuno-oncology research, creates cell therapy group

7 years ago

Gene silencing company NeuBase Therapeutics to reverse merge its way onto Nasdaq via troubled microcap Ohr

7 years ago

Bristol-Myers inks a $74B deal to buy out Celgene, expects $15B a year from late-stage pipeline

7 years ago

Merck goes all-in on a late-stage NASH drug from NGM as development race heats up

7 years ago

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

7 years ago

China greenlights second homegrown PD-1 in 10 days as Innovent celebrates its first drug OK with Eli Lilly

7 years ago

Acorda celebrates an FDA OK — so does that make them a takeover target?

7 years ago

FDA hits a green light on 2 more rare disease drugs, giving Alexion an early shot at protecting PNH franchise

7 years ago

Novartis' SMA gene-therapy, if priced at $2M, could be more cost-effective than Biogen's Spinraza — ICER

7 years ago

Boehringer offloads an mTOR cancer drug as Xynomic plots a quick advance in the clinic

7 years ago

Cash-poor Agenus finds itself a generous partner in Gilead, shares surge

7 years ago

After abruptly pulling its marketing application, DBV may be left with peanuts in race against Aimmune

7 years ago

FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment

7 years ago

Gilead dangles $105M in quick cash to sign Scholar Rock to a discovery deal for its growing NASH pipeline

7 years ago

With cancer in focus, Amgen taps Molecular Partners' preclinical immune-oncology asset for $50M upfront

7 years ago

First page Previous page 283 284 285286287 288 289 Next page Last page